SARS-CoV-2 Detection
COVID-19
Commercial (as service)Active
Key Facts
About Aldatu Biosciences
Aldatu Biosciences is a private, US-based biotech founded in 2014, specializing in adaptive PCR diagnostics for infectious diseases. Its proprietary PANDAA technology platform addresses a critical challenge in molecular diagnostics by allowing real-time PCR assays to remain effective against evolving viral variants, thereby ensuring long-term assay integrity. The company's pipeline targets high-need areas including HIV drug resistance testing and pandemic preparedness for pathogens like SARS-CoV-2, Lassa virus, Ebola, and Crimean-Congo Hemorrhagic Fever virus. Operating as a public benefit corporation, Aldatu leverages grant funding, such as NIH SBIR awards, to advance its platform and expand its diagnostic product portfolio.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |
| UOL COVID-19 Test | Uh-Oh Labs | Approved |
| Lagevrio (molnupiravir) | Ridgeback Biotherapeutics | Approved/EUA |
| CVXGA | CyanVac | Phase 2 |